Wall Street brokerages predict that Aevi Genomic Medicine Inc (NASDAQ:GNMX) will report earnings per share (EPS) of ($0.16) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aevi Genomic Medicine’s earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.15). Aevi Genomic Medicine posted earnings of ($0.23) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 30.4%. The company is scheduled to report its next earnings report on Thursday, November 1st.
On average, analysts expect that Aevi Genomic Medicine will report full year earnings of ($0.60) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.59). For the next financial year, analysts anticipate that the business will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.27) to ($0.57). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Aevi Genomic Medicine.
Aevi Genomic Medicine (NASDAQ:GNMX) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01.
NASDAQ:GNMX traded down $0.03 during trading hours on Tuesday, reaching $0.98. The company had a trading volume of 17,467 shares, compared to its average volume of 106,832. Aevi Genomic Medicine has a 52 week low of $0.83 and a 52 week high of $2.65.
Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of Aevi Genomic Medicine by 515.8% during the 4th quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 78,400 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Aevi Genomic Medicine by 4,715.1% during the 1st quarter. JPMorgan Chase & Co. now owns 101,118 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 99,018 shares during the last quarter. Finally, Wedbush Securities Inc. purchased a new position in shares of Aevi Genomic Medicine during the 2nd quarter worth $233,000. Institutional investors and hedge funds own 22.80% of the company’s stock.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Featured Story: Using the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.